Diamond Therapeutics Announces First Patient Enrolled in FDA-authorized Study Evaluating Low-Dose Psilocybin in Human Subjects with Demoralization ...Middle East

The trial is being conducted at the University of Alabama at Birmingham (UAB) under noted psychedelic researcher Dr. Peter Hendricks This exploratory study is the first investigation of the influence of low-dose psilocybin on human subjects suffering from demoralization TORONTO, Oct. 17,...

Hence then, the article about diamond therapeutics announces first patient enrolled in fda authorized study evaluating low dose psilocybin in human subjects with demoralization was published today ( Tuesday 17/10/2023 - 08:45 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Diamond Therapeutics Announces First Patient Enrolled in FDA-authorized Study Evaluating Low-Dose Psilocybin in Human Subjects with Demoralization )

Also on site :

• APOD: 2026 September 23 – A New Lunar Crater: McGetchin
• A Fat, Nude Woman Became a 1970s Merchandise Sensation. Who Was “Bridget in the Buff”?
• 1968 No. 1 Hit, Ranked Among ‘Greatest Songs of All Time,’ Became an 11-Minute Creedence Clearwater Classic